In 2025, significant advances have been made in the treatment of diabetes, providing new hope for patients. These innovations include new drugs, novel therapies, and advanced technologies that can improve blood sugar control and improve the quality of life of patients. Here are some of these achievements:
1. Smart insulin (NNC2215)
Novo Nordisk has developed a new insulin called NNC2215 that is sensitive to blood glucose levels. This insulin is designed to reduce its activity when blood sugar is low, which can reduce the risk of hypoglycemia.
2. Ultra-long-acting insulin (Insulin Icodec)
Insulin Icodec, brand name Awiqli, is an ultra-long-acting basal insulin that is injected only once a week. This feature can reduce the burden of treatment for patients and help improve adherence to treatment.
3. Oral drug Orforglipron
Orforglipron is a GLP-1 receptor agonist that is taken orally. The drug can lower blood sugar and help with weight loss, without the need for injections.
4. Cell therapy Lantidra (Donislecel)
Lantidra is the first approved cell therapy for type 1 diabetes. The treatment involves transplanting pancreatic islet cells from donors into patients, which can restore insulin production in the patients’ bodies.
5. Drug Petrelintide
Petrelintide is an amylin analog that is injected weekly and, when combined with semaglutide, can help with weight loss and blood sugar control. The drug is currently in early-stage clinical trials.
6. New technologies in diabetes management
Along with new drugs, advanced technologies have also been introduced for better diabetes management:
Hybrid closed-loop systems: such as mylife Loop, which helps to control blood sugar more accurately with smaller catheters and artificial intelligence.
Non-invasive blood sugar monitoring: Devices such as Glucowear™ that measure blood sugar levels without the need to pierce the skin.
Smart applications: such as GlucoFit, which analyzes blood sugar data to provide personalized recommendations for patients.
Summary
The year 2025 has seen significant advances in diabetes treatment. From new drugs with smart mechanisms to advanced technologies in disease monitoring and management, all these achievements promise a brighter future for diabetic patients. As research and development in this area continues, diabetes control is expected to become easier and more effective than ever.
7. Tirzepatide (Manjaro): A new generation of dual-acting drugs
Tirzepatide, known under the trade name Manjaro, is a dual-acting drug that stimulates both GLP-1 and GIP receptors. This drug was first approved for type 2 diabetes and then, in new studies, has shown significant effects on weight loss. Its mechanism of action is such that it both increases insulin secretion and reduces appetite. This duality in effect has made Manjaro one of the most effective drugs for simultaneous control of blood sugar and weight.
New studies show that Tirzepatide can lead to an average reduction of 10 to 15 percent of body weight, which is very impressive compared to other diabetes drugs. Also, this drug reduces the risk of cardiovascular diseases by improving insulin sensitivity.
8. VX-880: A revolutionary treatment for type 1 diabetes
VX-880 is a stem cell-based treatment developed by Vertex Pharmaceuticals. This treatment involves transplanting pancreatic beta cells that are capable of producing normal insulin. The goal of this treatment is to replace the beta cells lost in type 1 diabetes.
VX-880 uses a specific cell source that can be produced indefinitely, which overcomes the challenge of a shortage of donors. In early studies, some patients were able to control their blood sugar without the need for insulin injections with this treatment. However, this treatment is still in the experimental stages and needs further evaluation.
9. Retatrutide: Triple-Action Drug for Diabetes and Obesity
Retatrutide is a triple-action drug that simultaneously stimulates three receptors: GLP-1, GIP, and glucagon. This drug was introduced in 2025 as a new option for the control of type 2 diabetes.
In clinical studies, Retatrutide has not only helped lower blood sugar, but also had significant effects on weight loss. By combining three hormonal pathways, this drug reduces appetite, increases insulin secretion, and accelerates fat metabolism. These features have made Retatrutide one of the most effective combination drugs for diabetes and obesity.
10. INS-049: A drug for type 1 diabetes without the need for insulin
INS-049 is a new oral drug designed to replace insulin injections in type 1 diabetes patients. The drug acts through specific molecular pathways that stimulate beta cells to produce insulin.
Unlike injectable insulin, INS-049 is taken orally and does not require injections. The drug has shown positive results in early studies, but is still in the early stages of research and its efficacy and safety need to be evaluated on a larger scale.
11. Third-generation artificial pancreas technology: Smart blood sugar control
In 2025, artificial pancreas technology has been upgraded to its third generation. These systems now manage blood sugar more accurately and intelligently using artificial intelligence and machine learning.
The third-generation artificial pancreas includes a complete closed system that:
Measures blood sugar levels in real time.
Based on this data, it calculates and injects the amount of insulin needed.
Artificial intelligence algorithms predict sudden drops and spikes by analyzing blood sugar patterns.
These systems are especially useful for type 1 diabetes patients, as they reduce the need for momentary decision-making and calculating insulin doses.
12. CRISPR-Cas9 gene therapy for type 1 diabetes
In 2025, researchers used CRISPR-Cas9 gene editing technology to treat type 1 diabetes. This method involves genetically modifying pancreatic beta cells to restore their ability to produce insulin.
The CRISPR-Cas9 method allows the repair or replacement of defective genes that have led to the destruction of beta cells. Although this method is still in the experimental stages, it is considered a potential approach to definitively treat type 1 diabetes.
13. New biosimilar insulins: more economical options for diabetic patients
In 2025, several new biosimilar insulins have been launched on the market that have similar efficacy to well-known brand insulins but at a lower cost. These insulins are considered a cost-effective option, especially for patients who avoid insulin injections due to the high cost of treatment.
Biosimilars work like original insulins and can be used as injections or in an insulin pump. Some of them are also compatible with smart blood sugar monitoring systems, which allow for automatic dose adjustment.
Summary:
2025 has been a fruitful year for diabetes treatments. The arrival of multi-drug drugs such as Tirzepatide and Retatrutide, new technologies such as the third-generation artificial pancreas and gene therapies have opened up new prospects for diabetic patients. In addition, innovative treatments such as VX-880 and INS-049 have provided hope for replacing daily insulin injections.
However, many of these treatments are still in the experimental or final approval phases and require further research. Being aware of these developments and constantly following the status of new research can help patients benefit from the latest treatments and improve their quality of life.
14. Dual Agonists: A New Generation of Dual-Agent Drugs for Type 2 Diabetes
In 2025, dual-agent drugs aimed at combining the effects of GLP-1 and GIP receptors have entered the market. These drugs, such as Tirzepatide, not only help to better control blood sugar by simultaneously activating these two receptors, but also enhance the effects of weight loss.
Mechanism of action:
GLP-1: Increases insulin secretion in response to increased blood sugar and reduces glucagon secretion.
GIP: Increases insulin sensitivity and better regulates fat metabolism.
These drugs can help patients with type 2 diabetes who are also obese achieve two important goals with a single drug: blood sugar control and weight loss.
15. Zuranolone: A New Drug for Diabetic Neuropathy
Diabetic neuropathy is a common complication of diabetes that can lead to nerve damage. Zuranolone is a new drug that helps reduce nerve pain caused by diabetes through a different mechanism.
This drug is taken orally and affects the GABA receptor pathways that are involved in reducing nerve pain. Early studies have shown that Zuranolone can reduce the severity of neuropathic pain by up to 40%.
16. INZ-701: A new treatment to improve kidney function in diabetic patients
Kidney diseases, including kidney failure, are common complications of diabetes. In 2025, INZ-701 was introduced as a kidney-protecting drug for diabetic patients.
This drug prevents the destruction of kidney cells and improves kidney function by regulating specific metabolic pathways. Studies have shown that taking INZ-701 can slow the progression of kidney failure and postpone the need for dialysis.
17. Digital Platforms for Diabetes Management: Artificial Intelligence and Data Mining
In recent years, technological advances have led to the development of smart platforms for diabetes management. In 2025, these platforms will reach a more advanced level and will now use artificial intelligence and data mining to analyze patient data.
Examples:
DiabTrack: This app sends personalized alerts to patients by analyzing daily blood sugar levels and medication intake.
GlucoPredict: This platform uses machine learning to predict blood sugar trends and provide suggestions for adjusting insulin or medication doses.
InsuSense: A wearable sensor that measures blood sugar levels in real time without the need for needles and sends the data to an app.
These systems not only prevent severe hypos or hyperglycemia, but also help patients manage their disease more actively and consciously.
18. New drugs to prevent type 2 diabetes in people at risk
In 2025, drugs aimed at preventing type 2 diabetes have been introduced for people with prediabetes. These drugs are especially recommended for those with a high body mass index, a family history of diabetes, or metabolic syndrome.
Mounjaro: This drug, injected weekly, helps control weight and reduce insulin resistance by regulating the hormones GLP-1 and GIP.
Velaglucagon: This drug prevents prediabetes from progressing to type 2 diabetes by increasing insulin sensitivity.
Metformin XR: A new, long-acting version of metformin that helps regulate blood sugar and reduce the risk of developing type 2 diabetes.
19. Educational programs and psychological support for diabetic patients
In addition to medications, in 2025 there is a greater focus on the psychological and social aspects of diabetes management. Stress and depression can negatively affect blood sugar control.
DiabetesMind: This online program helps diabetic patients cope better with the stresses of the disease by providing psychological counseling sessions and mindfulness exercises.
DiabSupport: A platform for connecting diabetic patients with support groups that share their experiences and advice.
GlucoBalance: This program focuses on reducing anxiety and depression, helping patients achieve better blood sugar management.
20. Drug combinations for the simultaneous treatment of diabetes and cardiovascular diseases
Many diabetic patients are at high risk of cardiovascular diseases. In 2025, new drug combinations have been introduced that simultaneously affect both problems:
Empa-Care: This drug is a combination of empagliflozin (SGLT-2) and beta-blockers that both lower blood sugar and regulate blood pressure.
CardioGluco: A drug made by combining GLP-1 agonists with statins and helps reduce the risk of heart attack and control blood sugar.
HeartSafe: A combination of ACE inhibitors and long-acting insulins that not only keeps blood sugar stable, but also prevents damage to blood vessels.
Final summary:
The year 2025 has brought tremendous developments in the field of diabetes treatment. From new and combined drugs to digital platforms and wearable technologies, all these developments have been developed to improve blood sugar control, reduce diabetes complications and improve the quality of life of patients.
Focusing on multiple approaches, including drug treatments, advanced technologies, psychological supports, and prevention programs, can make positive changes in the lives of people with diabetes.
21. Anti-inflammatory drugs for diabetes: A new approach
Chronic inflammation is a major factor in the development of type 2 diabetes and its associated complications. In 2025, several anti-inflammatory drugs specifically designed for diabetic patients have entered the market:
Caniqualimab: This drug is a monoclonal antibody that binds to interleukin 6 (IL-6) receptors and blocks inflammatory pathways. Studies have shown that reducing systemic inflammation can reduce insulin resistance and improve blood sugar control.
Anakinra XR: A long-acting version of the drug Anakinra, which inhibits the interleukin 1 (IL-1) pathway. This drug is specifically prescribed for patients with diabetes and inflammatory diseases such as rheumatoid arthritis.
Aramchol: An oral drug that helps reduce inflammation and improve glucose metabolism by inhibiting hepatic fat synthesis. This drug is especially recommended for patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
22. Pancreatic function-enhancing drugs: Hope for type 1 diabetes patients
Traditional treatments for type 1 diabetes have focused on insulin replacement, but in 2025, drugs have been introduced that focus on beta cell regeneration and enhancing pancreatic function:
VX-264: This genetic drug helps stimulate beta cells in the pancreas to produce insulin.
IsletX: This drug contains cell growth factors that can regenerate beta cells and increase insulin production over time.
ImmuBeta: An immunotherapy drug that inhibits the destructive immune cells in type 1 diabetes and allows beta cells to regenerate.
23. Advanced blood sugar control with non-invasive technologies
In 2025, the development of non-invasive technologies for monitoring blood sugar levels has reached a new stage. These devices measure blood glucose levels without the need for blood or needles:
GlucoPatch: A smart patch that measures glucose concentration through the skin by sending weak electrical pulses.
GlucoLens: Glasses that monitor blood glucose levels by analyzing tear components. This technology is designed for people who wear contact lenses or glasses.
SkinSense: A wearable device that uses infrared light waves to measure blood glucose without the need for a blood sample.
In addition to high accuracy, these technologies have reduced the pain and stress caused by frequent blood sugar measurements.
24. Concurrent drugs for diabetes and Alzheimer’s: New connection discovered
Research has shown that diabetes can be a risk factor for Alzheimer’s. In 2025, drugs have been introduced that focus on the simultaneous treatment of diabetes and the prevention of Alzheimer’s:
Semaglutide XR: This drug, which was previously prescribed for type 2 diabetes, is now also used in higher doses to prevent Alzheimer’s.
GLP-1 Fusion: A drug that combines GLP-1 agonists and neurotrophic factors and, in addition to controlling blood sugar, also prevents the destruction of brain neurons.
DiabeMind: A supplement containing antioxidants and anti-inflammatory substances that helps improve cognitive function in diabetic patients.
25. New methods of treating obesity in diabetic patients: drugs and surgical interventions
Obesity, as a risk factor for type 2 diabetes, continues to attract the attention of researchers. In 2025, new methods of treating obesity have been introduced, especially for diabetic patients:
Cagrilintide: A new drug that increases the feeling of satiety and prevents false appetite.
Gastric Balloon XR: New gastric balloons that help with weight loss by gradually releasing appetite suppressant drugs.
EndoSleeve: A device that is endoscopically placed in the intestine and helps with weight loss and blood sugar control by reducing nutrient absorption.
26. New methods to improve cardiovascular health in diabetics
Diabetic patients are at high risk of cardiovascular disease. In 2025, new drugs and technologies have been introduced to improve heart health in these patients:
EmpaHeart: A drug made from a combination of empagliflozin and beta-blockers that, in addition to lowering blood sugar, also prevents heart failure.
CarboSafe: A wearable device that simultaneously monitors blood sugar levels and cardiac markers such as heart rate and blood pressure.
CardioRestore: A stem cell-based therapy that helps repair damaged blood vessels in diabetic patients.
27. The role of probiotics and botanicals in diabetes management
In recent years, more research has focused on probiotics and botanicals. As natural supplements, these substances can help improve glucose metabolism and reduce insulin resistance:
ProGluco: A probiotic supplement that boosts specific compounds of beneficial gut bacteria and helps regulate blood sugar.
Berberine XR: A herbal compound that works similarly to metformin and lowers blood sugar.
Curcumin-C: A turmeric extract formulation that has strong anti-inflammatory and antioxidant properties and helps reduce insulin resistance.
Final conclusion:
The 2025 advances in diabetes treatment clearly indicate the entry into a new era in the management of this chronic disease. Focusing on multifaceted approaches, including novel drugs, noninvasive devices, genetic therapies, and smart technologies, could make dramatic changes in blood sugar control and prevent diabetes complications.